Vaccine therapy in non-small-cell lung cancer.

Published

Journal Article (Review)

Lung cancer is the leading cause of death from cancer worldwide. First-line therapy is based on stage at diagnosis and can include chemotherapy, radiation, and surgery. Despite advances, the prognosis for advanced-stage lung cancer is very poor. Vaccines with the capability to activate the host immune system may have a role in second-line therapy. Advances in the understanding of cellular and molecular immunology are forming the basis for improving vaccine therapy. Most trials to date have demonstrated safety but inconsistent efficacy. Further research is needed to enhance this potential.

Full Text

Duke Authors

Cited Authors

  • Albright, C; Garst, J

Published Date

  • July 2007

Published In

Volume / Issue

  • 9 / 4

Start / End Page

  • 241 - 246

PubMed ID

  • 17588347

Pubmed Central ID

  • 17588347

International Standard Serial Number (ISSN)

  • 1523-3790

Language

  • eng

Conference Location

  • United States